KLP Kapitalforvaltning AS Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• KLP Kapitalforvaltning AS has reduced its stake in Regeneron Pharmaceuticals by 14.8%, now holding 41,488 shares worth approximately $21.78 million after selling 7,200 shares in the second quarter.
• Regeneron Pharmaceuticals reported earnings per share of $12.89 for the last quarter, significantly exceeding analysts' expectations of $8.43, along with a revenue of $3.68 billion, surpassing estimates of $3.30 billion.
• The company declared a quarterly dividend of $0.88 with a current annualized yield of 0.6% and a modest payout ratio of 8.87%.

KLP Kapitalforvaltning AS lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,488 shares of the biopharmaceutical company's stock after selling 7,200 shares during the period. KLP Kapitalforvaltning AS's holdings in Regeneron Pharmaceuticals were worth $21,781,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Finally, Colonial Trust Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.4%

Regeneron Pharmaceuticals stock opened at $583.24 on Wednesday. The stock has a 50-day moving average of $573.16 and a two-hundred day moving average of $566.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,024.36. The stock has a market cap of $61.82 billion, a PE ratio of 14.70, a price-to-earnings-growth ratio of 1.87 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $11.56 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research note on Friday, August 1st. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Finally, Citigroup reiterated a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.